BOSTON , April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment
BOSTON , April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the first quarter ended March 31, 2020 .
– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data readouts in 1H20 – – Company to host conference call and webcast today at 4:30
BOSTON , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Barclays Global Healthcare Conference in Miami on Wednesday, March 11, 2020
BOSTON , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended December
BOSTON , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase
BOSTON , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm.
– Encouraging long-term outcome data after infusion of Sleeping Beauty -modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome need for surgical resection published in Clinical Cancer Research – BOSTON , Jan.
BOSTON , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,
BOSTON , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019 .